Nicox SA
PAR:COX

Watchlist Manager
Nicox SA Logo
Nicox SA
PAR:COX
Watchlist
Price: 0.579 EUR -0.52% Market Closed
Market Cap: 28.9m EUR

Nicox SA
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Nicox SA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Nicox SA
PAR:COX
Other Current Liabilities
€2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other Current Liabilities
€40m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Other Current Liabilities
€53m
CAGR 3-Years
24%
CAGR 5-Years
40%
CAGR 10-Years
57%
Inventiva SA
PAR:IVA
Other Current Liabilities
€13m
CAGR 3-Years
84%
CAGR 5-Years
26%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Other Current Liabilities
$720k
CAGR 3-Years
-54%
CAGR 5-Years
-46%
CAGR 10-Years
-7%
Abivax SA
PAR:ABVX
Other Current Liabilities
€2.8m
CAGR 3-Years
-26%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
No Stocks Found

Nicox SA
Glance View

Market Cap
28.8m EUR
Industry
Biotechnology

Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

COX Intrinsic Value
Not Available

See Also

What is Nicox SA's Other Current Liabilities?
Other Current Liabilities
2.4m EUR

Based on the financial report for Dec 31, 2022, Nicox SA's Other Current Liabilities amounts to 2.4m EUR.

What is Nicox SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 1Y
8%

Over the last year, the Other Current Liabilities growth was 8%.

Back to Top